5th Annual Gene Therapy for Ophthalmic Disorders Summit
![Gene-Therapy-for-Ophthalmic-Disorders-Summit-TAG](https://prcclinical.com/wp-content/uploads/Gene-Therapy-for-Ophthalmic-Disorders-Summit-TAG-1269x219.jpg)
September 10-12, 2024
Boston, MA
The Gene Therapy for Ophthalmic Disorders Summit convenes industry leaders to explore cutting-edge advancements in gene therapies for eye diseases such as Age-Related Macular Degeneration (AMD) and Inherited Retinal Diseases (IRDs). This summit highlights innovations in vector engineering for enhanced retinal targeting, crucial endpoint selection for regulatory approval, and advancements in ocular delivery methods such as intravitreal and subretinal administration. Discussions also delve into the complexities of clinical trial design and execution, offering insights from successful trials and lessons learned from setbacks to accelerate therapeutic development.
PRC Clinical specializes in comprehensive trial management services for gene therapies in ophthalmic disorders across a platitude of indications and delivery methods. We ensure sponsors developing innovative gene therapies for ocular health maintain regulatory compliance and efficient clinical trial execution through our depth of expertise in advanced therapies and ophthalmology, with direct indication-experience in dry eye, achromatopsia, AMD, retinoschisis, and more. Fill out the form below to reserve a time to meet with PRC Clinical and strategize on your next ophthalmology trial.